Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells

Biochemical Pharmacology

Volumn 72, Issue 4, 2006, Pages 427-436

  Erlich, Shlomit ^a   Tal Or, Pazit ^a   Liebling, Ronit ^a   Blum, Roy ^a   Karunagaran, Devarajan ^b   Kloog, Yoel ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Prostate; Ras; Signal transduction; Transformation

Indexed keywords

ANDROGEN; CASPASE INHIBITOR; CYCLIN D1; FARNESYLTHIOSALICYLIC ACID; PROTEIN CDC42; PROTEIN KINASE B; RAS PROTEIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL DEATH; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

AMINO ACID CHLOROMETHYL KETONES; ANDROGENS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; E2F1 TRANSCRIPTION FACTOR; FARNESOL; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SALICYLIC ACIDS; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 33745950061     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.05.007     Document Type: Article

References (48)

1. Amanatullah D.F., Reutens A.T., Zafonte B.T., Fu M., Mani S., and Pestell R.G. Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. Front Biosci 5 (2000) D372-D390
2. Rubben H., Bex A., and Otto T. Systemic treatment of hormone refractory prostate cancer. World J Urol 19 (2001) 99-110
3. So A., Gleave M., Hurtado-Col A., and Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 23 (2005) 1-9
4. Harris A.L., Nicholson S., Sainsbury R., Wright C., and Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 11 (1992) 181-187
5. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Hittmair A., Zhang J., et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 28 (1996) 392-405
6. Culig Z., Hobisch A., Bartsch G., and Klocker H. Androgen receptor - an update of mechanisms of action in prostate cancer. Urol Res 28 (2000) 211-219
7. Scher H.I., Sarkis A., Reuter V., Cohen D., Netto G., Petrylak D., et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1 (1995) 545-550
8. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8 (2002) 3438-3444
9. Meyer D., and Birchmeier C. Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc Natl Acad Sci USA 91 (1994) 1064-1068
10. Sikes R.A., and Chung L.W. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 52 11 (1992) 3174-3181
11. Schwartz S.J., Caceres C., Morote J., De Torres I., Rodriguez-Vallejo J.M., Gonzalez J., et al. Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. Int J Oncol 14 (1999) 367-371
12. Shiraishi T., Muneyuki T., Fukutome K., Ito H., Kotake T., Watanabe M., et al. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Res 18 (1998) 2789-2792
13. Carter B.S., Epstein J.I., and Isaacs W.B. Ras gene mutations in human prostate cancer. Cancer Res 50 (1990) 6830-6832
14. Anwar K., Nakakuki K., Shiraishi T., Naiki H., Yatani R., and Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52 (1992) 5991-5996
15. Gioeli D., Mandell J.W., Petroni G.R., Frierson J.H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59 (1999) 279-284
16. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63 (2003) 1981-1989
17. Sepp-Lorenzino L., Tjaden G., Moasser M.M., Timaul N., Ma Z., Kohl N.E., et al. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 4 (2001) 33-43
18. Melisi D., Troiani T., Damiano V., Tortora G., and Ciardiello F. Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. Endocr Relat Cancer 11 (2004) 51-68
19. Shi Y., Wu J., Mick R., Cerniglia G.J., Cohen-Jonathan E., Rhim J.S., et al. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. Prostate 62 (2005) 69-82
20. Aharonson Z., Gana-Weisz M., Varsano T., Haklai R., Marciano D., and Kloog Y. Stringent structural requirements for anti-Ras activity of S-prenyl analogues. Biochim Biophys Acta 1406 (1998) 40-50
21. Haklai R., Weisz M.G., Elad G., Paz A., Marciano D., Egozi Y., et al. Dislodgment and accelerated degradation of Ras. Biochemistry 37 (1998) 1306-1314
22. Elad G., Paz A., Haklai R., Marciano D., Cox A., and Kloog Y. Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid. Biochim Biophys Acta 1452 (1999) 228-242
23. Marom M., Haklai R., Ben-Baruch G., Marciano D., Egozi Y., and Kloog Y. Selective inhibition of Ras-dependent cell growth by farnesylthiosalicylic acid. J Biol Chem 270 (1995) 22263-22270
24. McPherson R.A., Conaway M.C., Gregory C.W., Yue W., and Santen R.J. The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro. Prostate 58 (2004) 325-334
25. Marciano D., Ben-Baruch G., Marom M., Egozi Y., Haklai R., and Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J Med Chem 38 (1995) 1267-1272
26. Mosman T. J Immunol Methods 65 (1983) 55-63
27. Gana-Weisz M., Haklai R., Marciano D., Egozi Y., Ben-Baruch G., and Kloog Y. The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation. Biochem Biophys Res Commun 239 (1997) 900-904
28. Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58 (1998) 2720-2723
29. Leone G., DeGregori J., Sears R., Jakoi L., and Nevins J. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387 (1997) 422-426
30. Peeper D.S., Upton T.M., Ladha M.H., Neuman E., Zalvide J., Bernards R., et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386 (1997) 177-181
31. Sears R.C., and Nevins J.R. Signaling networks that link cell proliferation and cell fate. J Biol Chem 277 (2002) 11617-11620
32. Liu J.J., Chao J.R., Jiang M.C., Ng S.Y., Yen J.J., and Yang-Yen H.F. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 15 (1995) 3654-3663
33. Robles A.I., Rodriguez-Puebla M.L., Glick A.B., Trempus C., Hansen L., Sicinski P., et al. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12 (1998) 2469-2474
34. Nevins J.R. The Rb/E2F pathway and cancer. Hum Mol Genet 10 (2001) 699-703
35. Shalom-Feuerstein R., Lindenboim L., Stein R., Cox A.D., and Kloog Y. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor. Cell Death Differ 11 (2004) 244-247
36. Leloup C., Michaelson D.M., Fisher A., Hartmann T., Beyreuther K., and Stein R. M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways. Cell Death Differ 7 (2000) 825-833
37. Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., and Altieri D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351 (1998) 882-883
38. Okada E., Murai Y., Matsui K., Isizawa S., Cheng C., Masuda M., et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163 (2001) 109-116
39. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58 (1998) 15-20
40. Sommer K.W., Schamberger C.J., Schmidt G.E., Sasgary S., and Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene 22 (2003) 4266-4280
41. Limonta P., Dondi D., Marelli M.M., Moretti R.M., Negri-Cesi P., and Motta M. Growth of the androgen-dependent tumor of the prostate: role of androgens and of locally expressed growth modulatory factors. J Steroid Biochem Mol Biol 53 (1995) 401-405
42. Cohen D.W., Simak R., Fair W.R., Melamed J., Scher H.I., and Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 152 (1994) 2120-2124
43. Jansen B., Schlagbauer-Wadl H., Kahr H., Heere-Ress E., Mayer B.X., Eichler H., et al. Novel Ras antagonist blocks human melanoma growth. Proc Natl Acad Sci USA 96 (1999) 14019-14024
44. Yaari S., Jacob-Hirsch J., Amariglio N., Haklai R., Rechavi G., and Kloog Y. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res 11 (2005) 4321-4330
45. Blum R., Jacob-Hirsch J., Amariglio N., Rechavi G., and Kloog Y. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res 65 (2005) 999-1006
46. Gana-Weisz M., Halaschek-Wiener J., Jansen B., Elad G., Haklai R., and Kloog Y. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 8 (2002) 555-565
47. Emens L.A. Survivin' cancer. Cancer Biol Ther 3 (2004) 180-183
48. Kato H., Kato S., Kumabe T., Sonoda Y., Yoshimoto T., Kato S., et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6 (2000) 3937-3943